NetScientific (EMVC) AI Stock Analysis

• Market Cap: £12.77M
• Dividend Yield: N/A
• Average Volume (3M): 31.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.53
• Revenue Growth: 30.40%
• EPS Growth: 23.48%
• Country: UK
• Employees: 29
• Sector: Financial
• Sector Strength: 70
• Industry: Asset Management
• EPS (TTM): -0.04
• Shares Outstanding: 27,767,391
• 10 Day Avg. Volume: 35,929
• 30 Day Avg. Volume: 31,987
• PEG Ratio: -0.21
• Price to Book (P/B): 0.78
• Price to Sales (P/S): 4.82
• P/FCF Ratio: -5.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: 45.00p ▼(-1.10% Downside)

The overall stock score is primarily influenced by financial performance challenges, including profitability and cash flow issues. Technical analysis suggests neutral momentum, while valuation concerns due to negative earnings further impact the score. The absence of earnings call data and corporate events means these factors do not influence the score.

NetScientific Business Overview & Revenue Model

Company Description

EMV Capital plc is a venture capital firm specializing in seed, growth capital, early and mid stage investments. The firm focuses to invest in sustainability, life science, technology, transformative biomedical, deep tech, semiconductors, industrials, robotics, AI and healthcare technologies focusing on digital health, diagnostics, and therapeutics sectors. It also prefers to invest in companies that significantly improve the health and well-being of people with chronic diseases. Within digital health it focuses on data analytics, wearable technologies, and devices. The firm seeks to invest in companies based in European developed markets, United Kingdom and in the United States. It typically invests up to £15 million ($20.32 million), but may consider larger amounts. It prefers to hold a controlling interest in all principal subsidiaries. The firm prefers to invest through its balance sheet investments. EMV Capital plc was founded in 2008 and is based in London, United Kingdom with additional office in Beaconsfield, United Kingdom.

How the Company Makes Money

NetScientific generates revenue through a combination of equity stakes in its portfolio companies, strategic partnerships, and licensing agreements. The company typically invests in early-stage life sciences companies and retains a percentage of equity, which can appreciate significantly if the companies succeed. Additionally, NetScientific may receive milestone payments or royalties from the commercialization of products developed by these companies. Strategic partnerships with larger pharmaceutical or biotechnology firms can also lead to revenue-sharing arrangements, further contributing to the company's earnings.

NetScientific Financial Statement Overview

Summary

NetScientific shows potential for revenue growth but struggles with profitability and cash flow generation. The balance sheet indicates low leverage but highlights concerns with negative returns. The company needs to improve its operational efficiency and cash flow management to sustain long-term growth.

Income Statement

NetScientific has shown revenue growth with a notable increase from the previous year (69.5% in 2023 to 2024), indicating potential for expansion. However, the company is facing challenges with profitability, as evidenced by negative EBIT and net income margins, which suggest persistent operational inefficiencies and high costs.

Balance Sheet

The balance sheet reflects moderate financial stability. The debt-to-equity ratio is low, indicating low leverage, which is positive. However, the return on equity is negative due to consistent net losses, raising concerns about shareholder value generation. The equity ratio is strong, suggesting a solid equity base.

Cash Flow

Cash flow from operations remains negative, and free cash flow is deteriorating, reflecting liquidity constraints. Despite a positive free cash flow growth rate from 2023 to 2024, the company struggles to generate cash from operations, relying heavily on financing activities to fund operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.45M	1.45M	1.00M	1.11M	394.00K
Gross Profit	2.09M	1.23M	782.00K	989.00K	348.00K
EBITDA	-3.12M	-2.27M	-3.31M	-2.65M	-2.20M
Net Income	-3.06M	-2.64M	-3.09M	-2.38M	-1.61M
Balance Sheet
Total Assets	19.50M	22.46M	28.95M	20.69M	8.07M
Cash, Cash Equivalents and Short-Term Investments	949.00K	347.00K	580.00K	2.35M	1.03M
Total Debt	1.53M	2.53M	1.25M	654.00K	509.00K
Total Liabilities	5.43M	5.35M	3.71M	2.18M	1.17M
Stockholders Equity	15.10M	17.83M	25.84M	18.50M	6.74M
Cash Flow
Free Cash Flow	-1.97M	-3.51M	-3.16M	-3.54M	-2.88M
Operating Cash Flow	-1.78M	-3.14M	-2.56M	-3.48M	-2.79M
Investing Cash Flow	12.00K	1.11M	-1.08M	-3.46M	-959.00K
Financing Cash Flow	2.57M	1.39M	1.74M	8.02M	1.89M

NetScientific Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 45.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EMVC, the sentiment is Negative. The current price of 45.5 is below the 20-day moving average (MA) of 45.98, below the 50-day MA of 45.69, and above the 200-day MA of 45.32, indicating a neutral trend. The MACD of -0.29 indicates Positive momentum. The RSI at 40.81 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:EMVC.

NetScientific Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MAFL	71 Outperform	£12.51M	4.60	―	―	-79.36%	78.16%
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
FIPP	54 Neutral	£14.47M	―	―	―	-20.43%	-104.66%
EMVC	47 Neutral	£12.77M	-4.80	-14.80%	―	30.40%	23.48%
KRM	45 Neutral	$15.91M	-9.61	―	―	15.59%	54.47%

NetScientific Corporate Events

EMV Capital Reports Resilient Interim Results Amid Market Challenges

EMV Capital plc reported its interim results for the first half of 2025, highlighting a slight decrease in group revenue to £1.1 million and a reduction in group losses to £1.5 million. Despite challenging market conditions, the company’s assets under management remained above £100 million, with significant investments and strategic acquisitions, including assets from Destiny Pharma. The integration of Martlet Capital into EMV Capital’s structure has driven fair value growth and opened co-investment opportunities, while the Venture Building programme continues to progress, promising potential capital returns.

The most recent analyst rating on (GB:EMVC) stock is a Hold with a £47.00 price target. To see the full list of analyst forecasts on NetScientific stock, see the GB:EMVC Stock Forecast page.

EMV Capital Acquires Destiny Pharma’s XF Drug Platform

EMV Capital plc, through its subsidiary Moirai Acquisitions Limited, has acquired assets from Destiny Pharma Limited, including its XF drug platform, for up to £2.475 million. This acquisition, funded by third-party investment and equity fundraising, aims to advance the XF-73 compound, which offers a novel approach to combating antibiotic resistance. The transaction underscores EMV Capital’s commitment to high-impact investments, particularly in the area of Anti-Microbial Resistance, and is expected to enhance the company’s asset management portfolio and strategic positioning in the life sciences sector.

The most recent analyst rating on (GB:EMVC) stock is a Hold with a £47.00 price target. To see the full list of analyst forecasts on NetScientific stock, see the GB:EMVC Stock Forecast page.

EMV Capital to Release Interim Results and Host Investor Presentation

EMV Capital plc has announced that its interim results for the first half of 2025 will be released on September 30, 2025. The company will hold a live online presentation for analysts and investors on the same day, accessible via the Investor Meet Company platform. This event is open to all interested parties, allowing for questions to be submitted in advance or during the presentation. The announcement signifies EMV Capital’s commitment to transparency and engagement with its stakeholders, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (GB:EMVC) stock is a Hold with a £47.00 price target. To see the full list of analyst forecasts on NetScientific stock, see the GB:EMVC Stock Forecast page.